CompletedNCT01351272
Genetic Modulation of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)
Medication studyAges 18–50Germany
Understand this study
Who was this study for?
Listed age limits: 18 years to 50 years.
- Listed locations
- WürzburgSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMay 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 41
- Sponsor
- Wuerzburg University Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Germany
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT01351272
- Official title
Show the full official title
Genetic Modulation of Functional Brain Activity of Attention-deficit/Hyperactivity Disorder-related Working Memory Processes
Recruitment & locations
CompletedWürzburg
Questions about this study
Who is behind this study?
The study sponsor is Wuerzburg University Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Methylphenidate, non-retard and Placebo.
Who was this study for?
Listed age limits: 18 years to 50 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...